

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
11 December 2008 (11.12.2008)

PCT

(10) International Publication Number
WO 2008/150029 A1

(51) International Patent Classification:

C07D 407/04 (2006.01) **C07D 215/233** (2006.01)
C07D 409/04 (2006.01)

1-7-1, Doshomachi, Chuo-ku, Osaka-shi, Osaka, 5410045 (JP). **MORI, Atsushi** [JP/JP]; c/o OTSUKA PHARMACEUTICAL CO., LTD., 1-7-1, Doshomachi, Chuo-ku, Osaka-shi, Osaka, 5410045 (JP).

(21) International Application Number:

PCT/JP2008/060804

(74) Agents: **Saegusa & Partners** et al.; Kitahama TNK Building, 1-7-1, Doshomachi, Chuo-ku, Osaka-shi, Osaka 5410045 (JP).

(22) International Filing Date: 6 June 2008 (06.06.2008)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
2007-150819 6 June 2007 (06.06.2007) JP

(71) Applicant (for all designated States except US): **OTSUKA PHARMACEUTICAL CO., LTD.** [JP/JP]; 9, Kanda-Tsukasamachi 2-chome, Chiyoda-ku, Tokyo, 1018535 (JP).

(72) Inventors; and


(75) Inventors/Applicants (for US only): **OTSUBO, Kenji** [JP/JP]; c/o OTSUKA PHARMACEUTICAL CO., LTD., 1-7-1, Doshomachi, Chuo-ku, Osaka-shi, Osaka, 5410045 (JP). **OCHI, Yuji** [JP/JP]; c/o OTSUKA PHARMACEUTICAL CO., LTD., 1-7-1, Doshomachi, Chuo-ku, Osaka-shi, Osaka, 5410045 (JP). **NAKAI, Masami** [JP/JP]; c/o OTSUKA PHARMACEUTICAL CO., LTD.,

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: QUINOLONE COMPOUND AND PHARMACEUTICAL COMPOSITION



(1)

(57) Abstract: The present invention provides a quinolone compound represented by General Formula (1) or a salt thereof, wherein R₁ represents a hydrogen atom, etc.; R₂ represents a hydrogen atom, etc.; R₃ represents a phenyl group optionally being substituted with one or more substituents, etc.; R₄ represents a halogen atom; R₅ represents a hydrogen atom or halogen atom; R₆ represents a hydrogen atom; and R₇ represents a hydroxyl group, etc. The quinolone compound have a functional improvement effect, which suppresses progression of neurological dysfunction by inhibiting the chronic progression of Parkinson's disease or protecting dopamine neurons from the disease etiology, thereby prolonging the period before first administration begins.

WO 2008/150029 A1



Published:

- *with international search report*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*